—A Webinar from Decision Resources
Based on our U.S. Physician & Payer Forum report Physician and Payer Attitudes Towards Gilenya and Emerging Oral and Parenteral Disease-Modifying Therapies in the U.S. Multiple Sclerosis Market, Decision Resources is offering this exclusive webinar. Because this webinar will feature major report findings, it is ONLY available to purchasers of this Physician & Payer Forum report.
Please contact us to learn how you can purchase this report and attend the webinar.
In light of an expected doubling of the number of approved disease-modifying therapies (DMTs) for the treatment of multiple sclerosis by 2020, the drug market for this indication stands at the brink of transformation. As the DMT landscape evolves, treatment and reimbursement decisions are expected to be become increasingly complex as neurologists and payers grapple with an influx of premium-priced agents that each offer a unique mix of benefits and drawbacks, risks and rewards. Decision Resources surveyed 100 U.S. neurologists and 20 managed care organization (MCO) pharmacy directors to assess their attitudes, expectations, receptivity and reservations regarding currently marketed and late-stage emerging DMTs for the treatment of multiple sclerosis.
This webinar, presented by Decision Resources Senior Analyst Jonathan W. Searles, will answer the following questions:
- How have physicians incorporated Novartis/Mitsubishi Tanabe Pharma’s first-to-market oral DMT Gilenya into clinical practice to date? What are surveyed MCOs’ perceptions of this drug to date?
- How will the availability of a test that can identify patients at-risk for progressive multifocal leukoencephalopathy (PML) with Biogen Idec/Elan’s Tysabri impact the prescribing and reimbursement of the drug?
- To which patients, and to how many, do neurologists expect to prescribe Biogen Idec’s BG-12, Sanofi’s Aubagio, Teva/Active Biotech’s laquinimod and Genzyme/Sanofi/Bayer HealthCare’s Lemtrada? In what clinical situation(s) will these agents be prescribed? Which current agents are most at risk following the launch of these emerging therapies?
- Under premium price scenarios, how do surveyed MCOs expect to position late-stage emerging therapies on their formularies and what cost controls are they likely to impose?
- How receptive are payers and neurologists to emerging concepts like combination DMT or induction strategies? Which emerging agents are most likely to be used in combination and under what clinical circumstances would such an approach be employed?
Mr. Searles will conduct a live Q & A session after the presentation.
Multiple Sclerosis: Neurologist and Payer Receptivity to Gilenya, Tysabri and Late-Stage Emerging Agents that Could Reshape the Treatment Algorithm
December 14 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
Webinar Details Date & Time Presentation: 30 minutes Q & A: 15 minutes |
About the Speaker
|
Jonathan W. Searles is a senior analyst in the central nervous system disorders unit of Decision Resources, where he has authored numerous reports on multiple sclerosis, acute ischemic stroke, migraine, ADHD and cognitive dysfunction. Prior to joining Decision Resources, Mr. Searles received a B.A., summa cum laude, from Brandeis University. While earning his degree, Mr. Searles conducted research at the Harvard University Peabody Museum and at Brandeis.|
To learn how you can purchase this report and attend the webinar, please contact us using the information below. In North America In Europe In Japan |
Terms of Use | Privacy Policy | Contact Us | Careers
Decision Resources • 8 New England Executive Park • Burlington, MA 01803
You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.
© 2011 Decision Resources, LLC. All rights reserved.
